Homozygous deletion of an EGR2 enhancer in congenital amyelinating neuropathy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 22522483.
- Also identified by DOI 10.1002/ana.23527.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The transcription factor EGR2 is expressed in Schwann cells, where it controls peripheral nerve myelination. Mutations of EGR2 have been found in patients with congenital hypomyelinating neuropathy or Charcot-Marie-Tooth disease type 1D. In a patient with congenital amyelinating neuropathy, we observed pathological abnormalities recapitulating the peripheral nervous system phenotype of homozygous Egr2-null mice. This patient, born from consanguineous parents, showed no EGR2 immunoreactivity in Schwann cells and harbored a homozygous 10.7-kilobase-long deletion encompassing a myelin-specific enhancer of EGR2. This regulatory mutation is the first genetic abnormality associated with congenital amyelinating neuropathy in humans.
Medical subject headings
- Charcot-Marie-Tooth Disease
- Early Growth Response Protein 2
- Enhancer Elements, Genetic
- Myelin Sheath